VAXCYTE INC (PCVX:NASDAQ)
$65.84 -1.71 (-2.5315%)
Analysed VAXCYTE INC (PCVX:NASDAQ) News Sources
PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case
05-10-2026
stocktwits.com
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
05-10-2026
yahoo.com
NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test
05-10-2026
stocktwits.com
Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial
06-10-2026
marketbeat.com
Vaxcyte VAX-31 pneumococcal vaccine phase 3 trial results
06-10-2026
qz.com
As Expected: Vaxcyte Announces $1 Billion Stock and Convertible Raise a Day After Its Phase 3 Win (and Sinks 10%)
06-10-2026
tikr.com
Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers
06-10-2026
yahoo.com
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
07-10-2026
yahoo.com
Why Vaxcyte (PCVX) Is Getting Attention Again
08-10-2026
yahoo.com
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet
14-10-2026
yahoo.com
What is the current price of VAXCYTE INC (PCVX:NASDAQ)?
The current price of VAXCYTE INC (PCVX:NASDAQ) is $65.84.
VAXCYTE INC (PCVX:NASDAQ) absolute price change since previous trading day?
The absolute price change of VAXCYTE INC (PCVX:NASDAQ) since the previous trading day is $-1.71.
VAXCYTE INC (PCVX:NASDAQ) percentage price change since previous trading day?
The percentage price change of VAXCYTE INC (PCVX:NASDAQ) since the previous trading day is -2.5315%.
What is the most recent average sentiment score for VAXCYTE INC (PCVX:NASDAQ)?
The most recent average sentiment score for VAXCYTE INC (PCVX:NASDAQ) is 40 out of 100.
What is the most recent average sentiment for VAXCYTE INC (PCVX:NASDAQ)?
The most recent sentiment for VAXCYTE INC (PCVX:NASDAQ) is .
SEC-8K** Filing Available For VAXCYTE INC (PCVX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.